INTRODUCTION {#S1}
============

In contrast to the blood vasculature, the lymphatic vasculature experiences oscillatory fluid flow. Oscillatory fluid flow activates nuclear transcription factors that orchestrate the formation of intraluminal bileaflet valves that are dependent on fluid shear for their lifelong maintenance ([@R35]). Thus, in the absence of flow, lymphatic valves undergo regression ([@R42]). Since lymphatic vessels transport fluid from the tissues to the bloodstream against an increasing hydrostatic pressure, lymphatic valves serve to prevent retrograde lymph flow and edema.

Mutations in lymphatic valve genes have been identified in many human syndromes ([@R5]) and lead to lymphedema, severe tissue swelling characterized by fibrosis and infections. Lymphedema can also be acquired, most commonly after lymph node surgery in breast cancer patients ([@R31]; [@R41]). Valve defects likely instigate lymphedema because the most common gene mutations in human lymphedema occur in transcription factors regulating valve formation and because retrograde lymph flow is observed in patients ([@R34]). However, it remains unclear how fluid shear stress exerted on the cell membrane activates transcription factors located in the cell nucleus. The lack of a defined signaling pathway has precluded the development of new clinical therapies for lymphedema.

Endothelial cells sense fluid shear stress through the mechanotransduction pathway. In this pathway, PECAM1 senses shear stress and initiates SRC phosphorylation of VEGFR2 and VEGFR3 to activate PI3K/AKT signaling. These proteins are held in a complex by VE-cadherin ([@R1]; [@R46]). A role for PECAM1 in embryonic lymphatic valve formation was shown recently, supporting its role as a mechanosensor in the lymphatic vasculature ([@R47]). Whether VE-cadherin regulates mechanotransduction in the lymphatic vasculature remains unknown. While lymphatic-specific deletion of VE-cadherin causes lymphatic valve loss ([@R22]), it is unknown whether this is due to defective mechanotransduction signaling or due to vessel instability, as vascular structures have been reported to disintegrate upon loss of VE-cadherin ([@R6]; [@R21]). Here, we demonstrate that VE-cadherin regulates cell alignment with flow and its deletion inhibits lymphatic valve formation in the embryo and leads to severe valve regression in postnatal mice, prior to the onset of vessel disintegration and loss of integrity.

RESULTS {#S2}
=======

Generation and Validation of a Conditional VE-Cadherin Allele {#S3}
-------------------------------------------------------------

Oscillatory shear stress created by pulsatile lymph flow has been shown to be involved in the early steps of lymphatic valve formation ([@R35], [@R36]; [@R42]), indicating that a mechanotransduction signaling complex may be essential for this process. To test whether VE-cadherin was required for lymphatic valve development, we generated a conditional floxed *Cdh5* allele through homologous recombination ([Figure S1A](#SD1){ref-type="supplementary-material"}). Previous studies have demonstrated that global loss of VE-cadherin is embryonic lethal at embryonic day (E) \~10.5 ([@R6]; [@R21]). To test that our floxed allele disrupts *Cdh5* gene expression, we crossed it with the constitutive pan-endothelial *Tie2Cre* allele to obtain *Tie2Cre;Cdh5*^*flox/flox*^ embryos ([Figures S1B](#SD1){ref-type="supplementary-material"}, [S1C](#SD1){ref-type="supplementary-material"}, and [S1D](#SD1){ref-type="supplementary-material"}). As reported for global *Cdh5*^−/−^ embryos ([@R6]; [@R21]), *Tie2Cre;Cdh5-^flox/flox^* embryos at E10.5 exhibited stunted growth, a dilated pericardial sac, and underdeveloped vascular structures that were prone to hemorrhaging ([Figure S1D](#SD1){ref-type="supplementary-material"}). Additionally, the yolk sac vasculature was malformed and appeared as a collection of blood islands ([Figure S1C](#SD1){ref-type="supplementary-material"}). When pups were genotyped at birth from *Tie2Cre;Cdh5*^+/*fl*^ x *Cdh5*^*fl/fl*^ matings, the expected ratios of *Cdh5*^+/*fl*^*, Cdh5*^*fl/fl*^, and *Tie2Cre;Cdh5*^+/*fl*^ were born (30%, 24%, and 22%, respectively; n = 150 pups), but no conditional null *Tie2Cre;Cdh5*^*fl/fl*^ pups were obtained. To test whether pups could be obtained from matings with a constitutive lymphatic-specific Cre strain, we mated *Lyve1Cre;Cdh5*^+/*fl*^ with *Cdh5*^*fl/fl*^ and genotyped the pups at birth. The expected ratios of *Lyve1Cre;Cdh5*^+/*fl*^*, Cdh5*^+/*fl*^, and *Cdh5*^*fl/\ fl*^ mice were obtained (29%, 27%, and 19%, respectively; n = 64 pups), while no conditional null *Lyve1Cre;Cdh5*^*fl/fl*^ pups were produced. To determine whether we could obtain lymphatic-specific VE-cadherin null embryos at a later stage than pan-endothelial null embryos, we searched for *LyvelCre;Cdh5*^*fl/fl*^ embryos at E11.5, but found that they displayed stunted growth and appeared to be undergoing resorption (data not shown). Therefore, both *Lyve1Cre;Cdh5*^*fl/fl*^ and *Tie2-Cre;Cdh5*^*fl/fl*^ mice are embryonic lethal at \~E10.5, presumably due to the expression of *Lyve1* in the embryonic arterial and venous endothelium as well as the yolk sac vasculature ([@R20]).

Embryonic Lymphatic-Specific Deletion of VE-Cadherin Results in Lymphatic Valve Defects {#S4}
---------------------------------------------------------------------------------------

To study the role of VE-cadherin in the lymphatic vasculature during embryonic valve development, we resorted to using a tamoxifen-inducible lymphatic-specific CreER^T2^ strain with a high recombination efficiency ([@R4]). The *Cdh5*^*flox/flox*^ and *Prox1CreER*^*T2*^ strains were interbred to generate *Cdh5*^*flox/flox*^ controls and *Prox1CreER*^*T2*^*;Cdh5*^*flox/flox*^ knockout mice (hereafter referred to as *VE-cadherin*^*LEC-KO*^*).* To visualize the lymphatic vasculature in freshly dissected tissues, the Prox1-GFP reporter strain ([@R10]) was intercrossed with these strains. Inactivation of genes that are involved in lymphatic valve formation typically result in valve loss when they are quantified in the mouse mesentery ([@R3]; [@R27]; [@R35], [@R36]; [@R42]). We induced recombination of the VE-cadherin gene at E14.5, which is approximately 1 day after lymphatic endothelial cell (LEC) progenitors begin to form a mesenteric lymphatic plexus ([@R40]) ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). To determine whether loss of VE-cadherin resulted in embryonic lymphatic valve defects, embryos were collected at E18.5 and mesenteries were imaged immediately at low and high magnification. As shown in [Figure 1C](#F1){ref-type="fig"}, control mesenteries had several GFP^+^ lymphatic vessels that each contained numerous GFP^hi^ bright spots, which were confirmed to be lymphatic valves at higher magnification ([Figure 1D](#F1){ref-type="fig"}). In contrast, several dilated GFP^+^ lymphatic vessels were found in the *VE-cadherin*^*LEC-KO*^ mesenteries and no GFP^hi^ spots were ever visualized ([Figures 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}), indicating a complete absence of lymphatic valves. At high magnification, the lymphatic structures in the *VE-cadherin*^*LEC-KO*^ mesenteries were reminiscent of a lymphatic plexus that had failed to remodel into defined collecting vessels ([Figure 1F](#F1){ref-type="fig"}), similar to that reported for *Clec2*^−/−^ mice that lacked lymph flow ([@R42]).

Demonstrating that the lymphatic valve defects were not confined to the mesentery alone, we also assessed valve morphology in other tissues outside the abdomen ([Figure S2](#SD1){ref-type="supplementary-material"}). In the developing axillary lymphatic vessels that connect the inguinal and axillary lymph nodes at E18.5, the control lymphatic vessels were highly branched with numerous areas of valve formation that were completely absent in the *VE-cadherin*^*LEC-KO*^ ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}). Similarly, in embryonic back skin at E18.5, the developing lymphatic plexus contains several valve-forming areas denoted by GFP^hi^ spots that are completely absent from the *VE-cadherin*^*LEC-KO*^ back skin ([Figures S2C](#SD1){ref-type="supplementary-material"}--[S2F](#SD1){ref-type="supplementary-material"}). Further, we found that the lymphatic vessels appeared to migrate to the midline faster in the *VE-cadherin*^*LEC-KO*^ back skin and appeared to be disintegrating ([Figures S2C](#SD1){ref-type="supplementary-material"} and [S2D](#SD1){ref-type="supplementary-material"}). Together, these data indicate that VE-cadherin is required for lymphatic valve development in the embryo and for the maturation of the early lymphatic capillary plexus. As these two processes have previously been shown to require lymph flow *in vivo* ([@R42]), and oscillatory shear stress upregulates valve specification genes *in vitro* ([@R7]; [@R27]; [@R35]; [@R42]), we hypothesized that a mechanotransduction complex similar to that identified in blood vessels regulates lymphatic valve formation.

VE-Cadherin Deletion Impairs Valve Maturation {#S5}
---------------------------------------------

Lymphatic valve formation occurs in the embryonic mesentery from E16.5 to E18.5 ([@R18]; [@R30]; [@R35]; [@R45]). Since VE-cadherin-deficient lymphatic vessels completely lacked valves at E18.5, we checked the earliest stages of lymphatic valve formation at E16.5 and E17.5. Single PROX1^+^ cells first appear in the mouse mesentery at E13.5, which later assemble into vessel structures that then initiate valve development ([@R40]). The initiation of valve development first appears as PROX1^hi^ cell clusters at E16.5 in mouse mesentery ([@R18]; [@R40]). To assess the role of VE-cadherin in lymphatic valve formation, inactivation of the VE-cadherin gene was induced by injection of tamoxifen at E13.5 and E14.5, followed by harvesting mesenteries at E16.5 ([Figure S3A](#SD1){ref-type="supplementary-material"}). Control and *VE-cadherin*^*LEC-KO*^ mesenteries with the Prox1-GFP reporter possessed many GFP^hi^ spots that indicated the normal initiation of valve formation ([Figures S3B](#SD1){ref-type="supplementary-material"}--[S3E](#SD1){ref-type="supplementary-material"}). Both the morphology and number of GFP^hi^ areas appeared similar in the controls compared to the *VE-cadherin*^*LEC-KO*^ lymphatic vessels. To directly confirm the efficient deletion of VE-cadherin, mesenteries were immunostained for both VE-cadherin and PROX1 ([Figures S3F](#SD1){ref-type="supplementary-material"}--[S3I](#SD1){ref-type="supplementary-material"}). Again, control and *VE-cadherin*^*LEC-KO*^ lymphatic vessels both contained PROX1^hi^ cell clusters that indicated lymphatic valve formation was initiated normally and all PROX1^+^ vessels lacked VE-cadherin expression in the *VE-cadherin*^*LEC-KO*^ tissues. Together, these results demonstrate that VE-cadherin is dispensable for the specification of lymphatic valve cell clusters.

Next, we checked whether the lymphatic valve cell clusters that appeared at E16.5 entered into the second and third steps of valve formation, condensation and leaflet elongation, at E17.5 ([@R35]). VE-cadherin was deleted as before prior to harvesting mesenteries at E17.5 ([Figure S4A](#SD1){ref-type="supplementary-material"}). To check valve morphology, we performed immunostaining for PROX1 and Integrin-α9, a receptor for fibronectin EIIIA that is upregulated on lymphatic valve endothelium ([@R3]). In control E17.5 mesenteries, the valve-forming territories had upregulated PROX1 expression that was accompanied by increased expression of Integrin-α9 compared to the surrounding LECs ([Figures S4B](#SD1){ref-type="supplementary-material"} and [S4C](#SD1){ref-type="supplementary-material"}). The *VE-cadherin*^*LEC-KO*^ valve territories still expressed high levels of PROX1, similar to E16.5, and these areas were associated with higher levels of Integrin-α9 ([Figures S4D](#SD1){ref-type="supplementary-material"} and [S4E](#SD1){ref-type="supplementary-material"}). When their morphologies were compared, there appeared to be no defects in valve elongation as defined by [@R35]. The fourth and final step of valve formation is valve maturation that occurs between E17.5 and postnatal day (P) 7. No mature valve leaflets were observed at E18.5, precluding further analysis, and demonstrated that VE-cadherin is required for the valve maturation step of valve formation.

VE-Cadherin Is Required for Lymphovenous Valve Development in the Embryo {#S6}
------------------------------------------------------------------------

Recently, it was proposed that the embryonic edema in mutant mouse models of lymphatic disease is indicative of defects in the formation of the lymphovenous valves (LVVs), which form at the junction between the lymphatic and blood vasculatures to prevent blood from entering the lymphatic vessels ([@R17]). The first valve structures that form in the developing embryo are the leaflets of the LVVs, which begin protruding from the lymph sac at E12.5 into the future subclavian vein ([@R38]). Two layers of endothelial cells contribute to the LVV leaflets: lymphatic endothelium from the lymph sac and venous endothelium from the subclavian vein. By E16.5, well-defined valve leaflets extend from the lymph sacs into the subclavian vein ([@R17]). To determine whether loss of *VE-cadherin* affected the formation of the LVV, recombination was induced at E10.5, 1 day after the specification of LECs had begun but prior to the formation of the lymph sac and primitive lymphatic plexus ([@R39]; [@R48]) ([Figure 1G](#F1){ref-type="fig"}). Embryos were obtained at E14.5 and E16.5 and were sectioned frontally to visualize the LVV. Gross examination of the *VE-cadherin*^*LEC-KO*^ embryos at E14.5 and E16.5 revealed profound edema, indicating the presence of lymphatic vascular defects ([Figures 1H](#F1){ref-type="fig"}--[1K](#F1){ref-type="fig"}). At E14.5, the LVV leaflets appeared normal and seemed to make continuous connections with the subclavian vein in both the controls and knockouts ([Figures 1L](#F1){ref-type="fig"} and [1M](#F1){ref-type="fig"}). In contrast, the lymph sacs of the E16.5 *VE-cadherin*^*LEC-KO*^ embryos failed to upregulate PROX1, lacked valve leaflets, and remained completely disconnected from the subclavian vein ([Figures 1N](#F1){ref-type="fig"}--[1Q](#F1){ref-type="fig"}). This revealed that although *VE-cadherin* expression was dispensable for the early development of LVV valves at E14.5, the complete formation of the LVV leaflets required VE-cadherin.

LEC Nuclei Do Not Align with Flow in the Absence of VE-Cadherin {#S7}
---------------------------------------------------------------

A hallmark of endothelial mechanotransduction signaling is the ability of cells to align parallel to the direction of flow ([@R46]). Loss of VE-cadherin from blood vessel endothelium prevents cell alignment in the direction of flow ([@R46]), while loss of *Pecam1* or *Sdc4* from the lymphatic vasculature has been shown to prevent alignment of LECs with flow and rounder cells ([@R47]). To assess LEC alignment with flow, we measured whether PROX1^+^ nuclei were aligned in the direction of lymph flow in straight, unbranched vessels and measured the nuclear length-to-width ratio to assess roundness ([Figure 2](#F2){ref-type="fig"}). PROX1^+^ LEC nuclei in control lymphatic vessels at E18.5 appeared elongated along the vessel axis, compared with VE-cadherin-deficient LECs that appeared round and randomly oriented ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). When this was quantified, with 0° set parallel to the vessel length, control nuclei were within approximately 3° of the flow axis, while *VE-cadherin*^*LEC-KO*^ nuclei were on average oriented \~40° away from the flow axis with higher variability ([Figure 2C](#F2){ref-type="fig"}; 2.9 ± 0.6 versus 38.5 ± 7.4, n = 3, p \< 0.05). Similarly, the length-to-width ratio was higher in the control nuclei, indicating elongation, while this was significantly reduced in the *VE-cadherin*^*LEC-KO*^ nuclei ([Figure 2D](#F2){ref-type="fig"}; 3.7 ± 0.7 versus 1.6 ± 0.1, n = 3, p \< 0.05). Thus, VE-cadherin-deficient LECs do not align with flow. These data strongly implicate VE-cadherin in mechanotransduction signaling in the developing lymphatic vasculature.

VE-Cadherin Regulates Lymphatic Vessel Integrity and Valve Morphology Postnatally {#S8}
---------------------------------------------------------------------------------

Oscillatory shear stress upregulates *Prox1* and *Foxc2* in LECs, with *Foxc2* regulating the constant expression of connexins and calcineurin signaling to maintain the valve structures once they have formed ([@R35], [@R36]). Thus, persistent oscillatory flow induces constant cellular signaling pathways that prevent the regression of lymphatic valves during postnatal and adult life. This essential role for flow in lymphatic valve development was recently confirmed *in vivo* ([@R42]). If VE-cadherin is necessary for mechanotransduction signaling, then we would expect that its continued expression would be required for valve maintenance postnatally. Controls and *VE-cadherin*^*LEC-KO*^ pups were administered tamoxifen at P1 and P3 to completely delete *VE-cadherin* at a time when many lymphatic valves had already formed ([Figure 3A](#F3){ref-type="fig"}). Pups were then examined for gross lymphatic vascular defects at P8 and P14. At P14, but not at P8, we observed the accumulation of chylous ascites in the *VE-cadherin*^*LEC-KO*^ pups ([Figure 3C](#F3){ref-type="fig"}) but not in controls ([Figure 3B](#F3){ref-type="fig"}). When the mesenteric lymphatic vessels were examined directly under brightfield microscopy, we visualized leakage of milky fluid into the peritoneum from lymphatic collecting vessels, which appeared as a white haze around the vessels ([Figure 3E](#F3){ref-type="fig"}). This was expected due to the fact that VE-cadherin is also a crucial adherens junction protein that controls blood vessel endothelial integrity ([@R6]; [@R13]). Due to the absorption of dietary lipids, the lymphatic collecting vessels appeared white in both groups, which enabled the visualization of the valves. Normal V-shaped valves were apparent in the controls ([Figure 3F](#F3){ref-type="fig"}), but were not observed in any of the *VE-cadherin*^*LEC-KO*^ lymphatic collecting vessels ([Figure 3G](#F3){ref-type="fig"}). Instead, many lymphatic vessels were devoid of valves and the valve structures that were occasionally present were constricted ring structures that lacked leaflets ([Figure 3G](#F3){ref-type="fig"}).

Quantification of the Total Number of Lymphatic Valves Reveals a Valve Maintenance Defect {#S9}
-----------------------------------------------------------------------------------------

To enable quantification of the total number of valves in the control and *VE-cadherin*^*LEC-KO*^ mesenteries at P8 and P14, valves were visualized *in situ* with fluorescence microscopy ([Figures 3H](#F3){ref-type="fig"}--[3P](#F3){ref-type="fig"}).

The valves of control mesenteries at both stages exhibited the typical V shape and were composed of PROX1^hi^ LECs ([Figures 3J](#F3){ref-type="fig"} and [3O](#F3){ref-type="fig"}), whereas the lymphatic vessels in the *VE-cadherin*^*LEC-KO*^ mesenteries were either constricted ([Figure 3K](#F3){ref-type="fig"}) or possessed ring structures composed of PROX1^hi^ LECs ([Figure 3P](#F3){ref-type="fig"}). Long, perfectly formed valve leaflets were rare in the *VE-cadherin*^*LEC-KO*^ mesenteries. Small collateral branches at the defective valve sites were common ([Figure 3P](#F3){ref-type="fig"}). In P8 control mesenteries, numerous regularly spaced valves were counted, whereas the *VE-cadherin*^*LEC-KO*^ mesenteries had 75% fewer valves ([Figures 3H](#F3){ref-type="fig"}, [3I](#F3){ref-type="fig"}, and [3L](#F3){ref-type="fig"}) (743 ± 14 versus 173 ± 4, n = 3, p \< 0.05). Approximately 1 week later, the P14 *VE-cadherin*^*LEC-KO*^ mesenteries had 90% fewer valves than the controls (1,083 ± 48 versus 115 ± 8, n = 3, p \< 0.05), indicating that over time the valves were regressing ([Figures 3M](#F3){ref-type="fig"}, [3N](#F3){ref-type="fig"}, and 3Q). As the loss of lymphatic valves in the *VE-cadherin*^*LEC-KO*^ animals could also be explained by a loss of lymph flow instead of a direct loss of VE-cadherin signaling, we fed postnatal pups 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (BODIPY FL C~16~), a fluorescent lipid that is selectively absorbed by the lymphatic collecting vessels draining the intestine. Others have shown that without forward flow, mesenteric lymphatic collecting vessels will not fill with BODIPY FL C~16~ and, thus, will not exhibit any fluorescence ([@R42]). Mesenteric lymphatic collecting vessels from control and *VE-cadherin*^*LEC-KO*^ pups at P8 and P14 were filled with the fluorescent lipid 3 h after feeding ([Figure S6](#SD1){ref-type="supplementary-material"}), indicating that these vessels had patent lumens and forward flow. Another possibility is that loss of VE-cadherin might decrease the expression of other junction proteins prior to the loss of valves at P8, and the loss of several junction proteins would collectively lead to an enhanced permeability and reduction in lymph flow to indirectly cause valve regression. However, genetic deletion of VE-cadherin from adult blood vessel endothelium ([@R16]) or adult lymphatic endothelium ([@R22]) was recently shown to be without effect on the expression of other junction proteins or the ultrastructure of interendothelial junctions by electron microscopy. To determine whether the loss of other junction proteins from the postnatal lymphatic vasculature could explain the valve regression in P8 *VE-cadherin*^*LEC-KO*^ mice, we examined the tight junction proteins, Claudin-5 and ZO-1 ([Figure S5](#SD1){ref-type="supplementary-material"}). Similar to the adult lymphatic vasculature, we show that postnatal deletion of VE-cadherin at an early time point does not affect the expression of other junction proteins. Together, these data demonstrate that VE-cadherin signaling is required for postnatal valve maintenance, and postnatal valve regression occurs in the presence of lymph flow and prior to the onset of chylous ascites or altered junction protein expression.

VE-Cadherin Regulates PROX1 and FOXC2 Expression *In Vivo* and Inhibits Cell Death {#S10}
----------------------------------------------------------------------------------

Interestingly, the postnatal valve phenotypes of our *VE-cadherin*^*LEC-KO*^ mice appeared similar to another mouse model that has demonstrated postnatal valve regression, which is a conditional, lymphatic-specific deletion of *Foxc2,* a major transcription factor required for valve formation and maintenance ([@R36]). Thus, we hypothesized that VE-cadherin-mediated signaling regulated the expression of *Foxc2* through mechanotransduction signaling. Immunostaining was performed on E18.5 and P8 mesenteries to determine whether PROX1 and/or FOXC2 were downregulated upon loss of *VE-cadherin* ([Figure 4](#F4){ref-type="fig"}). At E18.5, collecting lymphatic vessels from control mesenteries exhibited well-defined valves that had higher PROX1 expression than the surrounding lymphangion cells and expressed VEGFR3 and VE-cadherin ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}). In contrast, the lymphatic collecting vessels from *VE-cadherin*^*LEC-KO*^ mesenteries expressed PROX1 uniformly in every LEC ([Figure 4C](#F4){ref-type="fig"}). We also verified our deletion efficiency by staining for VE-cadherin, which was deleted from \>95% of LECs ([Figure 4D](#F4){ref-type="fig"}). Similarly, control lymphatic collecting vessels demonstrated widespread expression of FOXC2 in every cell, as this is before the developmental stage when FOXC2 becomes restricted to the valve areas, but FOXC2 was highly upregulated in the valves ([Figures 4E](#F4){ref-type="fig"} and [4F](#F4){ref-type="fig"}). Upon loss of VE-cadherin, the expression of FOXC2 was uniform throughout the lymphatic vasculature at a level similar to non-valve lymphangion cells ([Figures 4G](#F4){ref-type="fig"} and [4H](#F4){ref-type="fig"}). Postnatal loss of *Foxc2* has been shown to cause valve regression through apoptosis in a caspase-3-dependent manner ([@R36]). Embryonic loss of VE-cadherin similarly led to clusters of apoptotic cells around branched regions in the *VE-cadherin*^*LEC-KO*^ lymphatic collecting vessels ([Figures 4K](#F4){ref-type="fig"} and [4L](#F4){ref-type="fig"}), while no staining was observed in the controls ([Figures 4I](#F4){ref-type="fig"} and [4J](#F4){ref-type="fig"}). To investigate how the postnatal loss of VE-cadherin affected the expression of PROX1 and FOXC2, VE-cadherin deletion was induced at P1/P3 and immunostaining was performed on P8 mesenteries. In control mesenteries, PROX1^hi^ cells were observed in the valve regions ([Figures 4M](#F4){ref-type="fig"} and [4N](#F4){ref-type="fig"}), whereas in *VE-cadherin*^*LEC-KO*^ lymphatic collecting vessels, LECs expressed PROX1 uniformly ([Figures 4O](#F4){ref-type="fig"} and [4P](#F4){ref-type="fig"}). At P8, FOXC2 expression appeared more restricted to the valve regions in the controls ([Figures 4Q](#F4){ref-type="fig"} and [4R](#F4){ref-type="fig"}), but these FOXC2^hi^ cells were mostly absent in the *VE-cadherin*^*LEC-KO*^ lymphatic vessels, and every LEC expressed uniform levels of FOXC2 ([Figures 4S](#F4){ref-type="fig"} and [4T](#F4){ref-type="fig"}). In later stages (\> P14), we found that FOXC2 staining in control mesenteries only labels the valve LEC, whereas in the *VE-cadherin*^*LEC-KO*^ mesenteries, FOXC2 could not be detected by immunostaining (data not shown). Together, these data indicate that VE-cadherin signaling enables the proper regulation of PROX1 and FOXC2 expression during valve development and sustains high FOXC2 expression in the valve cells throughout postnatal life. VE-cadherin deletion was recently shown to affect YAP/TAZ protein expression ([@R22]), and YAP/TAZ signaling regulates PROX1 expression and lymphatic valves ([@R9]). In control valves TAZ was highly expressed in the LEC nuclei, but in *VE-cadherin*^*LEC-KO*^ valves TAZ was downregulated ([Figures 4U](#F4){ref-type="fig"}--[4X](#F4){ref-type="fig"}).

VE-Cadherin Is Required for Lymphatic Endothelial Shear Stress Responses In *Vitro* {#S11}
-----------------------------------------------------------------------------------

Our data indicate that VE-cadherin is essential for the formation and maintenance of lymphatic valves, at least in part by modulating PROX1 and FOXC2 expression. However, whether VE-cadherin is able to regulate these and other transcription factors involved in valve development in response to oscillatory shear stress (OSS) is unknown. To address this issue, we cultured human dermal LECs in the absence or presence of OSS and transfected LECs in both conditions with a scrambled small hairpin RNA (shRNA) or with a targeted shRNA against *CDH5.* qRT-PCR was then performed to determine the changes in expression of several genes known to be involved in lymphatic valve development or responses to endothelial shear stress ([Figure 5](#F5){ref-type="fig"}). Since β-catenin directly binds VE-cadherin ([@R43]) and regulates embryonic lymphatic valve development by binding the promoter regions of *Prox1* and *Foxc2* ([@R7]), we also inhibited the degradation of β-catenin with the chemical inhibitor 6-bromoindirubin-3'-oxime (BIO), a GSK3β antagonist.

The total amount of *CDH5* protein was reduced by \~95% by the shRNA construct compared to the scrambled construct ([Figure 5A](#F5){ref-type="fig"}). Additionally, treatment of the LECs with BIO increased FOXC2 protein expression in both static (no flow) and oscillatory flow conditions ([Figure 5A](#F5){ref-type="fig"}). At the message level, the major transcription factors controlling valve development, *GATA2* and *FOXC2,* were upregulated significantly in response to OSS in the scramble control transfected LECs, but their expression did not change in response to OSS in the *CDH5*-knockdown LECs ([Figure 5B](#F5){ref-type="fig"}). BIO treatment of scramble control LECs exposed to OSS increased the expression of *GATA2* and *FOXC2* further than OSS alone, while BIO treatment of *CDH5* knockdown LECs exposed to OSS significantly increased the expression of *GATA2* and *FOXC2* to near control levels. Similarly, the earliest shear-responsive transcription factor ([@R14]; [@R23]; [@R37]), *KLF4,* was upregulated significantly in response to OSS in scramble control LECs, but was downregulated in the *CDH5*-knockdown LECs and did not change in response to OSS. Another gene known to be upregulated in the lymphatic valves is Connexin 37 *(GJA4),* whose expression is controlled by PROX1 and FOXC2 ([@R35]). Our data show that *CX37* was upregulated in response to OSS only in the scramble control LECs, whereas in the *CDH5* knockdown LECs *CX37* expression did not change in response to OSS, and its overall expression was lower. However, BIO treatment did not significantly increase the expression of either *KLF4* or *CX37* in scramble control or *CDH5* knockdown LECs, but instead reduced *KLF4,* but not *CX37,* expression. Since *AXIN2* is a known direct target of nuclear β-catenin signaling ([@R25]), we determined whether it responded to OSS. *AXIN2* expression was upregulated in response to OSS in the scramble control LECs, indicating β-catenin nuclear activity in response to OSS, but did not change in response to OSS in the *CDH5* knockdown LECs. As expected, the expression of AXIN2 was significantly increased by BIO treatment regardless of transfection with scramble control or *CDH5* knockdown shRNA. While PROX1 is normally highly expressed in the valve LECs *in vivo,* previous reports have established that it is not upregulated *in vitro* in response to OSS ([@R7]; [@R42]). For a negative control, we found that the expression of both *PROX1* and *VEGFR3* did not change in response to OSS in either the scramble control or *CDH5* knockdown LECs, as expected. Confirming a previous study ([@R7]), PROX1 expression was increased by BIO treatment in both static and OSS conditions.

Since these data indicated that β-catenin signaling was inhibited in the absence of VE-cadherin, we performed immunostaining ([Figure 5C](#F5){ref-type="fig"}) and western blot ([Figure 5D](#F5){ref-type="fig"}) for β-catenin. Indeed, when VE-cadherin expression was silenced, β-catenin expression was nearly abolished. This finding indicated that β-catenin expression depends on sequestration at the membrane by binding VE-cadherin and that β-catenin nuclear activity is responsible for changes in gene expression in response to OSS. To test this *in vivo*, we performed immunostaining for β-catenin in control and VE-cadherin^LEC-KO^ collecting lymphatic vessels and valves ([Figure 5E](#F5){ref-type="fig"}). We found that *in vivo,* loss of VE-cadherin led to a near complete loss of β-catenin.

VE-Cadherin/β-Catenin Signaling *In Vivo* Links Mechanotransduction to Valve Maintenance {#S12}
----------------------------------------------------------------------------------------

Because our *in vitro* data showed that stimulation of β-catenin signaling was able to enhance the expression of some valve-specific transcription factors in LECs lacking VE-cadherin, we next attempted to confirm whether constitutively active β-catenin signaling *in vivo* could rescue the lymphatic valve maintenance defect in our *VE-cadherin*^*LEC-KO*^ animals. Conditional deletion of exon 3 from the β-catenin gene *(Ctnnb1)* prevents the targeting of β-catenin for degradation by the destruction complex ([@R24]). Therefore, we crossed the previously published *Ctnnb1*^*lox(ex3\>*^ allele with our control and *VE-cadherin*^*LEC-KO*^ mice expressing the Prox1-GFP reporter. Confirming our previous data, loss of VE-cadherin resulted in a significant loss of 90% of lymphatic valves compared to controls at P16 ([Figures 6A](#F6){ref-type="fig"}--[6D](#F6){ref-type="fig"} and [6G](#F6){ref-type="fig"}) (1,081 ± 42 versus 143 ± 4, n = 3, p \< 0.05). However, the simultaneous overactivation of nuclear β-catenin signaling significantly rescued the maintenance defect and increased the number of remaining valves to 43% of control ([Figures 6E](#F6){ref-type="fig"}--[6G](#F6){ref-type="fig"}) (460 ± 33 versus 143 ± 4, n = 3, p \< 0.05). To examine whether the valve morphology was also rescued, we performed high-magnification confocal imaging ([Figures 6H](#F6){ref-type="fig"}--[6M](#F6){ref-type="fig"}). The control vessels had mature bileaflet valves that were positive for Integrin-α9 and VE-cadherin ([Figures 6H](#F6){ref-type="fig"} and [6I](#F6){ref-type="fig"}). As expected, the *VE-cadherin*^*LEC-KO*^ lymphatic vessels were negative for VE-cadherin and the valve areas appeared to be regressing with faint Integrin-α9 expression ([Figures 6J](#F6){ref-type="fig"} and [6K](#F6){ref-type="fig"}). In contrast, the *VE-cadherin*^*LEC-KO*^ valves that expressed a constitutive active β-catenin appeared similar to the control valve leaflets and expressed high levels of Integrin-α9 despite the absence of VE-cadherin ([Figures 6L](#F6){ref-type="fig"} and [6M](#F6){ref-type="fig"}). We performed further characterization of this rescue experiment by examining PROX1, FOXC2, GATA2, and KLF4 expression *in vivo* ([Figure S7](#SD1){ref-type="supplementary-material"}). All of these transcription factors had lower expression in regressing valves that was restored by constitutive activation of β-catenin. Thus, these data are consistent with mechanotransduction signaling through VE-cadherin at the cell membrane enabling the nuclear translocation of β-catenin and subsequent upregulation of the flow-sensitive genes involved in valve maintenance.

Direct Activation of AKT Partially Rescues Postnatal Valve Regression Caused by Loss of VE-Cadherin {#S13}
---------------------------------------------------------------------------------------------------

We found that cultured LECs exposed to OSS had increased expression of phosphorylated AKT, but this response was inhibited by knockdown of VE-cadherin ([Figure 5D](#F5){ref-type="fig"}). Because shear stress activates VEGFR/PI3K/AKT signaling downstream of VE-cadherin in vascular endothelium, we investigated this pathway further ([@R11]). Postnatal pups were administered a small molecule that directly activates AKT (SC79) daily from P2-P7 ([@R26]). To confirm that SC79 activated AKT signaling in LEC, we performed immunostaining for AKT target genes ([Figures 7A](#F7){ref-type="fig"}--[7D](#F7){ref-type="fig"}). Previous studies demonstrated that FOXC2 is a downstream target of VEGFR3/PI3K/AKT signaling ([@R32]; [@R44]). As expected, vehicle-treated lymphatic vessels expressed high levels of FOXC2 in the valve leaflets, but very low expression in the neighboring lymphangion LECs ([Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). In contrast, lymphatic vessels from mice treated with SC79 expressed FOXC2 not only in the valves, but also in many LECs outside of the valve areas in a mosaic pattern ([Figures 7C](#F7){ref-type="fig"} and [7D](#F7){ref-type="fig"}). Therefore, SC79 appeared to be activating the AKT pathway to stimulate ectopic FOXC2 expression in the non-valve LECs. To determine how AKT activation affected lymphatic valve development, VE-cadherin deletion was induced at P1/P3 as before and SC79 or vehicle was administered to postnatal pups ([Figures 7E](#F7){ref-type="fig"}--[7M](#F7){ref-type="fig"}). Control mesenteries treated with SC79 contained \~30% more lymphatic valves than control mesenteries treated with the vehicle alone ([Figures 7E](#F7){ref-type="fig"}--[7H](#F7){ref-type="fig"} and [7M](#F7){ref-type="fig"}) (790 ± 15 versus 1,010 ± 12, n = 4--5, p \< 0.05). Inactivation of VE-cadherin resulted in a 76% loss of lymphatic valves, as before, and treatment with SC79 partially inhibited this lymphatic valve regression ([Figures 7I](#F7){ref-type="fig"}--[7L](#F7){ref-type="fig"} and [7M](#F7){ref-type="fig"}) (190 ± 21 versus 349 ± 13, n = 3, p \< 0.05), restoring the total number of lymphatic valves to 45% of control. High-magnification imaging revealed that SC79 treatment of control *Cdh5*^*fl/fl*^ mice did not affect valve morphology ([Figures 7F](#F7){ref-type="fig"} and [7H](#F7){ref-type="fig"}). However, SC79 treatment of the *VE-cadherin*^*LEC-KO*^ lymphatics stimulated the growth of morphologically mature valves ([Figures 7J](#F7){ref-type="fig"} and [7L](#F7){ref-type="fig"}). These data show that AKT activation stimulates valve formation in healthy lymphatic vessels and that AKT signaling regulates valve maintenance downstream of VE-cadherin.

DISCUSSION {#S14}
==========

Oscillatory fluid flow is a major inducer of lymphatic valve development. Several studies have demonstrated that OSS induces the upregulation of lymphatic valve-specific transcription factors in cultured LECs ([@R7]; [@R27]; [@R35]; [@R42]) and *in vivo* ([@R42]). However, the mechanism by which LECs convert mechanical force exerted at the cell membrane into cell signals to regulate nuclear gene expression has remained elusive. Here, we identify VE-cadherin, a protein located at the cell membrane in adherens junctions, as a regulator of the formation and maintenance of lymphatic valves. We found that VE-cadherin was required for cell alignment to flow, and for the upregulation of lymphatic valve transcription factors *in vivo* during valve development and *in vitro* in response to OSS.

Control of Transcription Factors by VE-Cadherin {#S15}
-----------------------------------------------

The present study elucidated how membrane signals are transmitted to the nucleus to regulate gene expression. VE-cadherin forms protein complexes at the cell membrane and two of its binding partners are known to regulate lymphatic gene expression. VE-cadherin binds β-catenin, which was recently shown to be necessary for lymphatic valve formation in the embryo ([@R7]). Here, we show that VE-cadherin prevents the cytosolic degradation of β-catenin. VE-cadherin also binds VEGFR2 and VEGFR3 through its transmembrane domain to elicit AKT signaling ([@R11]). Since the ratio of VEGFR3 to VEGFR2 is known to dictate the cell sensitivity to shear stress, it stands to reason that LECs are highly sensitive to low levels of shear due to a high expression level of VEGFR3. Additionally, AKT signaling has been shown to regulate lymphatic valve development ([@R50]), potentially by modulating *Foxc2* expression ([@R32]; [@R44]). We show that AKT signaling is impaired in the absence of VE-cadherin. Thus, we propose that these two signaling pathways operate in parallel to regulate lymphatic valve maturation and maintenance. Supporting the involvement of these two signaling pathways, our data demonstrate that constitutive activation of β-catenin rescued the upregulation of *GATA2* and *FOXC2 in vitro* in response to shear and significantly restored the total number of lymphatic valves *in vivo* to approximately half of controls. We also showed that knockdown of VE-cadherin *in vitro* or knockout of VE-cadherin *in vivo* resulted in a dramatic loss of β-catenin protein at the cell membrane. In aggregate, these findings suggest that the junctional pool of β-catenin is responsible for nuclear signaling. Our results agree with a recent study showing that β-catenin directly binds to the promoters of *Prox1* and *Foxc2,* and that β-catenin signaling can regulate GATA2 protein expression ([@R7]). To directly stimulate AKT signaling, we used a well-characterized pharmacologic activator of AKT and found that this was able to significantly rescue the number of lymphatic valves to half of control levels. Mechanistically, we show that stimulation of the AKT pathway leads to ectopic expression of FOXC2 outside of valve leaflet LECs and this likely leads to new valve growth. Thus, our data show that AKT and β-catenin signaling work together to control valve formation, and both are necessary to prevent valve regression.

Role for VE-Cadherin in Valve Maturation {#S16}
----------------------------------------

With respect to the earliest events of valve formation in the embryo, we show that VE-cadherin expression does not regulate the initiation (or specification) step of valve formation or the condensation or elongation steps of valve formation. Instead, it appears that VE-cadherin is particularly required for the valve maturation step that takes place between E17.5 and E18.5 because we did not observe any valve structures at E18.5 in the absence of VE-cadherin. Similarly, we found that the LVV leaflets began to form at E14.5, but were completely absent at E16.5. However, a previous study demonstrated that lymph flow is required for lymphatic valve formation at E16.5 in the mesentery, the earliest time that PROX1^hi^ cell clusters can be observed in this tissue ([@R42]). Together with our results, it seems to suggest that separate shear stress signaling pathways are likely responsible for discrete steps of valve formation and that while VE-cadherin regulates some aspects of shear stress signaling, it is likely not responsible for all of mechanotransduction signaling in the lymphatic valves. Consistent with this idea, the mechano-sensitive ion channel PIEZO1 was recently shown to regulate only the condensation and elongation steps of valve formation ([@R15]; [@R29]). Another explanation is that some residual β-catenin protein could remain in the cytoplasm in the VE-cadherin-deficient LEC to respond to Wnt ligands to initiate valve specification ([@R8]).

VE-Cadherin in Lymphatic Mechanotransduction Signaling {#S17}
------------------------------------------------------

The present study demonstrates that a member of the blood endothelial cell (BEC) mechanotransduction pathway is required for lymphatic valve development. A separate study demonstrated that PECAM1, which acts as a mechanosensor upstream of VE-cadherin in BECs ([@R46]), regulates lymphatic valve formation in the embryo along with SDC4 ([@R47]). While the double-knockout mice exhibited severe lymphatic valve defects and reduced survival, the *Pecam1*^−/−^ embryos in that study had a relatively subtle defect in valve development and survived well into adulthood, arguing against an essential role in valve maintenance. In contrast, we show that the loss of VE-cadherin leads to defective cell alignment, severe regression of lymphatic valves, loss of PROX1^hi^ and FOXC2^hi^ cell clusters, abnormal branches at the postnatal regressing valves, and LEC apoptosis at the branch points of the embryonic lymphatic plexus. These phenotypes are reminiscent of the postnatal deletion of *Foxc2,* after which TAZ signaling becomes upregulated, leading to unchecked proliferation and apoptosis ([@R36]). Another report showed that lymphatic-specific deletion of VE-cadherin also leads to increased expression of TAZ ([@R22]). In contrast, we found that VE-cadherin deletion led to a near complete loss of TAZ expression in the collecting lymphatic vessels and valve LECs. The reason for the difference in TAZ expression is likely because [@R22] examined the expression of TAZ in hyperproliferative LEC sheets that grew in adult mesenteries after loss of VE-cadherin, whereas the present study is focused on the postnatal expression of TAZ in the valves and lymphangions of collecting lymphatic vessels that are not hyperproliferative. Our result is consistent with the finding that TAZ expression is decreased in the intestinal lacteal LECs reported by [@R22]. Our data are also consistent with another study that found that genetic deletion of both YAP and TAZ results in a near-complete loss of valves ([@R9]). Future studies should investigate whether lymphatic valves in this model can be rescued by targeting YAP/TAZ signaling.

Regulation of Lymphatic Integrity {#S18}
---------------------------------

While VE-cadherin regulates vascular mechanotransduction, it is also a well-established regulator of endothelial permeability ([@R12]; [@R19]) and its differential expression in the lymphatic vasculature helps establish discontinuous ''button'' junctions in the lymphatic capillaries and continuous ''zipper'' junctions in the larger lymphatic collecting vessels ([@R2]). As expected, we show that the early postnatal deletion of VE-cadherin results in chylous ascites and severe lymph leakage. Since it is possible that increased lymphatic vessel permeability or vessel disintegration may lead to a reduction in lymph flow, the loss of valves may be interpreted as an indirect effect due to vessel disintegration and not due to mechanotransduction signaling events. However, our data strongly argue against these possibilities. First, we did not observe chylous ascites or leaky, hazy lymphatic vessels at P8, but they were consistently present at P14. Additionally, we did not observe lymphatic vessel disintegration at P8, when valve number was already reduced by 75%, or at E18.5, when valves are completely absent. Thus, the loss of lymphatic valves in our mouse model precedes lymphatic vessel leakage. Second, we demonstrated that VE-cadherin-deficient mice had lymph flow at the same time point as littermate controls using a fluorescent lipid at both P8 and P14. Finally, loss of lymph flow in the mesenteric lymphatic vessels causes the lymphatics to no longer appear visibly white ([@R49]). We found that VE-cadherin-deficient lymphatic vessels were consistently filled with white chyle at P8 and P14.

Conclusion {#S19}
==========

In conclusion, our data explain how fluid forces at the LEC membrane regulate nuclear transcription factors to control valve formation and maintenance. We found that augmenting AKT signaling is capable of stimulating valve formation in otherwise wild-type mice. Future studies are needed to investigate the AKT signaling pathway to identify therapeutic targets to safely enhance valve formation in lymphedema patients.

STAR★METHODS {#S20}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S21}
---------------------------------------

Request for reagents must be directed to the Lead Contact, Joshua Scallan (<jscallan@health.usf.edu>). Upon completion of a Material Transfer Agreement (MTA), we will share any reagents.

EXPERIMENTAL MODELS AND SUBJECT DETAILS {#S22}
---------------------------------------

### Mice {#S23}

Generation of the *Cdh5*^*flox*^ allele is described in [Figure S1](#SD1){ref-type="supplementary-material"}. The *Tie2Cre, LyvelCre, Prox1CreER*^T2^, *Prox1-GFP, β-catenin*^*ex3(loxP\>*^ strains were described previously ([@R28]; [@R33]; [@R4]; [@R10]; [@R24]). *Prox1CreER*^*T2*^*;Cdh5*^*fl/fl*^*;Prox1-GFP* and *Pmx1CreER*^*T2*^*;Cdh5*^*ml*^*;β-catenin*+^*/ex3(loxP)*^*;Prox1-GFP* mice were generated by crossbreeding. All mice were maintained on a mixed genetic background (NMRI x C57BL/6J x SV129) and both sexes were used. Embryonic deletion of VE-cadherin was induced by intraperitoneal injections of 5 mg tamoxifen each into pregnant dams at the indicated developmental stages. Pups were injected twice with 100 μg tamoxifen in 5 μL sunflower oil subcutaneously on postnatal days P1 and P3. To directly activate AKT, the small molecule SC79 ([@R26])(Millipore Sigma) or vehicle (DMSO) was injected into pups (40 mg/kg, i.p.) once daily from P2 to P7 and pups were sacrificed on P8. All experiments were performed in accordance with the University of South Florida guidelines and were approved by the institutional IACUC committee.

### Cell Lines {#S24}

Primary human dermal lymphatic endothelial cells (hdLEC, Lonza and PromoCell) were cultured on fibronectin-coated six-well plates and were maintained in EBM-2 media (Lonza and PromoCell). All experiments were performed using cells at passage 6-7 and verified to express PROX1, a marker of lymphatic identity.

METHOD DETAILS {#S25}
--------------

### Whole Mount Immunostaining Procedure {#S26}

All procedures were carried out at 4°C on an orbital shaker (Belly Dancer, IBI Scientific) unless otherwise specified. Tissues were harvested and fixed overnight in 1% paraformaldehyde. The next day, tissues were washed with PBS three times 10 minutes each, permeabilized with PBS + 0.3% Triton X-100 (PBST) for one hour, and blocked with 3% donkey serum in PBST for two hours. Primary antibodies were mixed in PBST, added to the tissue, and incubated overnight. To remove primary antibodies, tissues were washed five times 15 minutes each with PBST. Secondary and conjugated antibodies were mixed in PBST, added to the tissues, and incubated at room temperature for two hours on an orbital shaker (Belly Button, IBI Scientific). Tissues were then washed five times 15 minutes each with PBST. To provide nuclear contrast, DAPI was dissolved in PBS, added to the tissues, and incubated at room temperature for 5 minutes, followed by a wash in PBS for 5 minutes. Tissues were then mounted on glass slides (Superfrost Plus Microscope slides, Fisherbrand) with ProLong Diamond Antifade Mountant containing DAPI (Invitrogen) and stored at 4°C overnight before imaging on an inverted fluorescence microscope (Axio Observer Z1, Zeiss) or a Leica SP8 confocal microscope. Images were acquired with Zen 2 Pro software and figures were created using Adobe Photoshop. Individual primary and secondary antibodies are listed in the [Key Resources table](#T1){ref-type="table"}.

### Lymphangiography {#S27}

Postnatal pups (at P8 or P14) were fed 1 μL of 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (BODIPY FL C~16~, ThermoFisher Scientific) that was dissolved in pure olive oil at a concentration of 10 μg/μL. Three hours after feeding, pups were euthanized and the mesenteric lymphatic vasculature was imaged immediately with a fluorescence stereo zoom microscope (Zeiss Axio Zoom V16).

### Lymphatic Valve Quantification {#S28}

Postnatal pups expressing the Prox1-GFP reporter strain were euthanized on postnatal day P8 or P14, and a loop of intestine was exteriorized through a midline incision and pinned onto a cushion made of Sylgard 184. Lymphatic valves, visualized as GFP^hi^ spots, were counted individually *in situ* in each section of the mesentery with the aid of a hand tally counter beginning at the duodenum and terminating at the cecum. The number of valves for each section was then totaled. Control and knockout littermates were analyzed in pairs or triplets from at least 3 independent litters.

### Cell Culture and Oscillatory Shear {#S29}

Cells were infected with lentiviral particles expressing an shRNA targeting *CDH5* ora control scramble construct expressing GFP for 48 hours. Subsequently, hdLEC were cultured in the presence of oscillatory shear stress (OSS) for 48 hours in the presence of DMSO or BIO (0.5 mM). RNA was then extracted and analyzed by quantitative real-time PCR (qRT-PCR) for selected genes, with RNA normalized to GAPDH. The OSS experiments were performed according to our previously published protocol ([@R7]). Specifically, hdLEC were cultured to 95% confluency in six-well plates and exposed to OSS using a test tube rocker (Thermolyne Speci-Mix aliquot mixer, model M71015, Barnstead Internat ional) with a preset frequency of 18 rpm. Cells in each well were covered with 1 μL of fluid. Based on previously described calculations, the cells were exposed to a total shear stress of 0.3 dynes/cm^2^. The entire experiment was performed inside a sterile humidified incubator containing 5% CO~2~.

### RNA Isolation, qRT-PCR, and Western Blot Analyses {#S30}

For quantitative real-time PCR, total RNA was isolated from human dermal lymphatic endothelial cells (hdLECs; Lonza and Promo-Cell) using TRIZOL reagent (Invitrogen) according to the manufacturer's protocol. cDNA was synthesized from total RNA (0.1 −1.0 μg) with Superscript III First-Strand Synthesis System (Invitrogen). qRT-PCR was performed using SYBR Green PCR Master Mix reagent (Bio-Rad) in a CFX96 Real-Time System (Bio-Rad). PCR conditions were 95°C (5 min) and 40 cycles at 95°C (30 s) and 60°C (1 min). The threshold cycle (Ct) value for each gene was normalized to the Ct value for GAPDH. The primer sequences are listed in [Table S1](#SD1){ref-type="supplementary-material"}.

For western blot, hdLECs were lysed in lysis buffer \[20mM Tris-HCl (pH 7.5), 150mM NaCl, 1.0% Triton X-100, 20mM NaF, 2mM EDTA, 2mM Na-orthovanadate, 1mM phenylmethylsulfonyl fluoride (PMSF), 5 mg/ml leupeptin A\]. Lysates were centrifuged for 15 min at 15,000 g in a cold room and the supernatant was collected and used for immunoblotting. Equal amounts of protein were resolved on 10% SDS-PAGE and transferred to a PVDF membrane. After blocking with 5% nonfat skim milk in TBS with 0.1% Tween-20 for 1 hour, the membranes were incubated with the indicated antibodies overnight at 4°C. Bound antibodies were visualized by ECL (Thermo Fisher Scientific) using HRP-conjugated antibodies. The antibodies used for western blot are listed in the [Key Resources Table](#T1){ref-type="table"}.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S31}
---------------------------------------

All data are represented as means ± SEM. For datasets containing exactly two groups, an unpaired two-sided Student's t test was used to determine significant differences (p \< 0.05). For datasets with more than two groups, one-way ANOVA with Tukey's posthoc analysis was performed to test for significant differences, where p \< 0.05 was considered significant. Graphpad Prism software (version 6) was used for all statistical analyses and to plot quantitative data.

DATA AND CODE AVAILABILITY {#S32}
--------------------------

This study did not generate/analyze datasets or code.
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![Embryonic Deletion of VE-Cadherin Causes Loss of Lymphatic Valves\
(A) Alleles used to delete VE-cadherin from lymphatic endothelium while simultaneously enabling the visualization of Prox1-expressing cells.\
(B) Schematic of the tamoxifen schedule used to delete VE-cadherin from the embryonic mesentery. TM, tamoxifen.\
(C--F) Direct fluorescence imaging of GFP (green) of freshly dissected mesenteries from E18.5 *Cdh5^flox/flox^* (C and D) and Prox1CreERT2;Cdh5f^lox/flox^ (E and F) embryos.\
(D and F) High-magnification images of the areas outlined by the white dashed boxes in (C) and (E), respectively. White arrows indicate lymphatic valves. Images are representative of n = 3 or more mesenteries per genotype. (See also [Figure S2](#SD1){ref-type="supplementary-material"} for loss of lymphatic valves in embryonic back skin and axillary regions.)\
(G) Tamoxifen schedule used for early embryonic deletion of VE-cadherin. TM, tamoxifen.\
(H and I) E14.5 control (H) and *VE-cadherin^LEC-KO^* (I) embryos. White arrowheads denote severe edema.\
(J and K) E16.5 control (J) and *VE-cadherinL^EC-KO^* (K) embryos. White arrowheads denote edema.\
(L and M) Immunostaining of frontal sections of E14.5 control (L) and *VE-cadherin^LEC-KO^* (M) embryos for PROX1 (green) and PECAM1 (red). LS, lymph sac; SCV, subclavian vein; IJV, internal jugular vein.\
(N and O) Immunostaining of frontal sections of E16.5 control (N) and *VE-cadherin^LEC-KO^* (O) embryos for VEGFR3 (green), GFP (red), and PECAM1 (blue). White arrows indicate lymphovenous valves while yellow arrows indicate venous valves only.\
(P and Q) Immunostaining of frontal sections of E16.5 control (P) and *VE-cadherin^LEC-KO^* (Q) embryos as in (N) and (O), but omitting the green channel to show Prox1-GFP expression (red channel).\
Scale bars are 200 μm in (C)--(F); 2 μm in (H)--(K); and 100 μm for (L)--(Q).](nihms-1538475-f0001){#F1}

![VE-Cadherin Is Required for Lymphatic Endothelial Cell Alignment with Flow in the Embryo\
(A and B) E18.5 mesenteries from control (A) and *VE-cadherin*^*LE-KO*^ (B) embryos immunostained for PROX1.\
(C) Nucleus orientation was measured using NIH FIJI software. The flow axis was defined as 0° and the absolute values of the angles were reported.\
(D) Nucleus roundness was measured as the length-to-width ratio.\
All values are means ± SEM of n = 3 independent experiments. \*p \< 0.05. Scale bars are 50 μm.](nihms-1538475-f0002){#F2}

![Postnatal Loss of VE-Cadherin Leads to Chylous Ascites and Loss of Valves\
(A) Tamoxifen schedule used for postnatal deletion of VE-cadherin. TM, tamoxifen.\
(B and C) Chylous ascites fluid of *VE-cadherin^LEC-KO^* mice (C, black arrowhead) compared to control (B).\
(D and E) Lymph leakage from mesenteric lymphatic collecting vessels of *VE-cadherin^LEC-KO^* mesentery (E) compared to control (D).\
(F and G) Valve structures in the lymphatic collecting vessels of control (F, white arrow) and *VE-cadherin^LEC-KO^* (G, yellow arrows) mesenteries. Insets are zoomed-in views of the valves indicated by the arrows.\
(H and I) *In situ* fluorescence imaging of the mesenteric lymphatic vasculature at P8. Images are of control (H) and *VE-cadherin^LEC-KO^* (I) tissues expressing the Prox1-GFP reporter (green) at low magnification.\
(J and K) High-magnification images of P8 lymphatic valves of control (J) and *VE-cadherin^LEC-KO^* (K) mesenteries.\
(L) The total number of lymphatic valves in P8 control and *VE-cadherin^LEC-KO^* mesenteries.\
(M and N) *In situ* fluorescence imaging of the mesenteric lymphatic vasculature at P14 expressing the Prox1-GFP at low magnification for control (M) and *VE-cadherin^LEC-KO^* (N).\
(O and P) High-magnification images of P14 lymphatic valves of control (O) and *VE-cadherin^LEC-KO^* (P) mesenteries.\
(Q) The total number of lymphatic valves in the P14 mouse mesentery of control and *VE-cadherin^LEC-KO^* animals. Unpaired Student's t tests were performed to compare the total valve number between control and *VE-cadherin^LEC-KO^* tissues at P8 and P14 (n = 3 per genotype per stage).\
All values are means ± SEM. \*p \< 0.05. Scale bars are 5 mm in (B) and (C); 500 μm in (D) and (E); 250 μm in (F) and (G); and 200 μm in (H)--(P).](nihms-1538475-f0003){#F3}

![VE-Cadherin-Deficient Lymphatic Valve Endothelial Cells Fail to Upregulate Prox1 and Foxc2 and Undergo Apoptosis\
(A and C) Whole mount immunostaining of mesenteries collected from E18.5 control (A) and *VE-cadherin^LEC-KO^* (C) embryos for VEGFR3 (green), PROX1 (red), and VE-cadherin (blue).\
(B and D) The same images as in (A) and (C) showing only PROX1 (red) in control (B) and *VE-cadherin^LEC-KO^* (D).\
(E-H) Whole mount immunostaining of mesenteries collected from E18.5 control (E) and *VE-cadherin^LEC-KO^* (G) embryos expressing the Prox1-GFP reporter for GFP (green), FOXC2 (red), and 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI; blue). Images of only FOXC2 (red) are shown for control (F) and *VE-cadherin^LEC-KO^* (H).\
(I--L) Whole mount immunostaining of mesenteries collected from E18.5 control (I) and *VE-cadherin^LEC-KO^* (K) embryos for VEGFR3 (green), Casp3 (red), and PECAM1 (blue). Images without VEGFR3 are shown for control (J) and *VE-cadherin^LEC-KO^* (L).\
(M and O) Whole mount immunostaining of mesenteries collected from P8 control (M) and *VE-cadherin^LEC-KO^* (O) pups for VEGFR3 (green), PROX1 (red), and VE-cadherin (blue).\
(N and P) The same images as in (M) and (O) showing only PROX1 (red) for control (N) and *VE-cadherin^LEC-KO^* (P).\
(Q--T) Whole mount immunostaining of mesenteries collected from P8 control (Q) and *VE-cadherin^LEC-KO^* (S) pups for PECAM1 (green), FOXC2 (red), and DAPI (blue). Images of only FOXC2 (red) are shown for control (R) and *VE-cadherin^LEC-KO^* (T).\
(U--X) Whole mount immunostaining of mesenteries collected from P8 control (U) and *VE-cadherin*^*LEC-KO*^ (W) pups for PROX1 (green), TAZ (red), and VE-cadherin (blue). Images of only TAZ (red) are shown for control (V) and *VE-cadherin*^*LEC-KO*^ (X). Insets at the lower right of some panels are the expanded views of the areas outlined by white boxes.\
Scale bars are 100 μm.](nihms-1538475-f0004){#F4}

![VE-Cadherin-Dependent Signaling Is Required for Transcription Factor Upregulation in Response to Oscillatory Flow *In Vitro*\
(A) Western blot of FOXC2 and CDH5 in human dermal lymphatic endothelial cells (hdLECs) cultured for 48 h in the absence or presence of oscillatory flow with or without a targeted shRNA against CDH5. Cells were treated with vehicle or with a GSK3-β antagonist (BIO).\
(B) qRT-PCR was performed for the indicated genes using hdLECs cultured under no flow (black bars) or oscillatory flow (red bars), transfected with a control scramble or shRNA against CDH5 (as indicated), and treated with vehicle or BIO (gray and blue bars). All values are means ± SEM of n = 3 experiments. One-way ANOVA was performed with Sidak's post hoc test for multiple comparisons (\*p \< 0.05).\
(C) hdLECs cultured under no-flow (static) conditions and immunostained for DAPI (blue), VE-cadherin (violet), PROX1 (red), and β-catenin (green) after infection with a scramble or shRNA targeting CDH5 for 48 h.\
(D) Western blot for β-catenin, pAKT, and total AKT in hdLECs under static or OSS conditions (for 5 min) treated with scramble or shRNA against CDH5.\
(E) Immunostaining for Prox1-GFP (green), VE-cadherin (red), and β-catenin (violet) in control and *VE-cadherin^LEC-KO^* lymphatic vessels.\
Scale bars are 50 μm in (C) and 100 μm in (E).](nihms-1538475-f0005){#F5}

![Constitutively Active β-Catenin Signaling Partially Rescues Valve Regression in the Absence of VE-Cadherin\
(A--F) Direct fluorescence imaging of Prox1-GFP (green) of freshly dissected mesenteries from P16 *Cdh5^fl/fl^*, *VE-cadherin^LEC-KO^*, and *VE-cadherin^LEC-KO^;Ctnnb1^+/lox(ex3)^* pups at low (A, C, and E) and high (B, D, and F) magnification.\
(G) Quantification of the total number of valves in the mesenteries from each genotype. All values are means ± SEM of n = 3 littermates per genotype.\
(H--M) Confocal imaging of lymphatic valves stained for Integrin-α9, GFP, and VE-cadherin from control (H and I), *VE-cadherin^LEC-KO^* (J and K), or rescue conditions(L and M) to show valve morphology.\
One-way ANOVA with Tukey's post hoc test was performed for multiple comparisons (\*p \< 0.05). Scale bars are 500 μm in (A), (C), and (E); 200 μm in (B), (D), and(F); and 50 μm in (H)--(M).](nihms-1538475-f0006){#F6}

![Direct Activation of Akt Partially Restores Valve Maintenance in the Absence of VE-Cadherin\
(A-D) P8 wild-type lymphatic vessels from mice treated with vehicle (DMSO; A and B) or the small molecule AKT activator SC79 (C and D) and immunostained for FOXC2 (red) and VE-cadherin (green).\
(E-L) Direct fluorescence imaging of Prox1-GFP (green) of freshly dissected mesenteries from P8 pups treated as indicated at low(E, G, I, and K) and high (F, H, J, and L) magnification.\
(M) Quantification of the total number of valves in the mesenteries from each genotype. All values are means ± SEM of n = 3 experiments per genotype.\
One-way ANOVA with Tukey's post hoc test was performed for multiple comparisons (\*p \< 0.05). Scale bars are 100 μm for(A)-(D); 500 μm for (E), (G), (I), and (K); and 100 μm for (F), (H), (J), and (L).](nihms-1538475-f0007){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                           SOURCE                     IDENTIFIER
  ----------------------------------------------------------------------------- -------------------------- ---------------------------------------------------------------
  Antibodies                                                                                               
  Rabbit polyclonal anti-Prox1                                                  abcam                      Cat\# ab101851; RRID: AB_10712211
  Goat polyclonal anti-Prox1                                                    R&D                        Cat\# AF2727; RRID: AB_2170716
  Rabbit polyclonal anti-Prox1                                                  AngioBio                   Cat\# 11-002; RRID: AB_10013720
  Rat monoclonal anti-VE-cadherin                                               BD                         Cat\# 550548; RRID: AB_2244723
  Rabbit polyclonal anti-VE-cadherin                                            ThermoFisher               Cat\# 36-1900; RRID: AB_2533243
  Rabbit polyclonal anti-VE-cadherin                                            Enzo                       Cat\# ENZ-ABS661-0100
  Sheep polyclonal anti-Foxc2                                                   R&D                        Cat\# AF6989; RRID: AB_10973139
  Mouse monoclonal anti-Foxc2                                                   Santa Cruz                 Cat\# SC-515234;
  Goat polyclonal anti-Vegfr3                                                   R&D                        Cat\# AF743; RRID: AB_355563
  Rat monoclonal anti-Pecam1                                                    BD                         Cat\# 550274; RRID: AB_393571
  Rabbit polyclonal anti-GFP                                                    Life Technologies          Cat\# A11122; RRID: AB_221569
  Rabbit polyclonal anti-Casp3                                                  Cell Signaling             Cat\# 9661; RRID: AB_2341188
  Rabbit polyclonal anti-Taz                                                    Sigma-Aldrich              Cat\# HPA007415; RRID: AB_1080602
  Rabbit polyclonal anti-Phospho-Akt (Ser473)                                   Cell Signaling             Cat\# 9271; RRID: AB_329825
  Rabbit monoclonal anti-Akt (pan) (C67E7)                                      Cell Signaling             Cat\# 4691; RRID: AB_915783
  Mouse monoclonal anti-β-Catenin (L54E2)                                       Cell Signaling             Cat\# 2677; RRID: AB_1030943
  Rabbit polyclonal anti-β-Catenin                                              Millipore                  Cat\# 06-734; RRID: AB_310231
  Goat polyclonal anti-Klf4                                                     R&D                        Cat\# AF3158; RRID: AB_2130245
  Goat polyclonal anti-Integrin α9                                              R&D                        Cat\# AF3827; RRID: AB_2128452
  Rabbit polyclonal anti-Gata2                                                  Novus Biologicals          Cat\# NBP1-82581; RRID: AB_11026191
  Rabbit polyclonal anti-Claudin 5                                              ThermoFisher               Cat\# 34-1600; RRID: AB_2533157
  Rabbit polyclonal anti-ZO-1                                                   ThermoFisher               Cat\# 61-7300; RRID: AB_2533938
  Mouse monoclonal anti-ACTB                                                    Sigma-Aldrich              Cat\# A5441; RRID: AB_47674
  Alexa Fluor 488 conjugated GFP                                                Life Technologies          Cat\# A21311; RRID: AB_221477
  Alexa Fluor 488 Donkey Anti-Rabbit IgG (H+L)                                  Life Technologies          Cat\# A21206; RRID: AB_141708
  Alexa Fluor 488 Donkey Anti-Goat IgG (H+L)                                    Life Technologies          Cat\# A11055; RRID: AB_2534102
  Alexa Fluor 488 Donkey Anti-Sheep IgG (H+L)                                   Life Technologies          Cat\# A11015; RRID: AB_141362
  Alexa Fluor 488 Donkey Anti-Rat IgG (H+L)                                     Life Technologies          Cat\# A21208; RRID: AB_141709
  Alexa Fluor 594 Donkey Anti-Rabbit IgG (H+L)                                  Life Technologies          Cat\# A21207 RRID: AB_141637
  Alexa Fluor 594 Donkey Anti-Goat IgG (H+L)                                    Life Technologies          Cat\# A11058; RRID: AB_2534105
  Alexa Fluor 594 Donkey Anti-Sheep IgG (H+L)                                   Life Technologies          Cat\# A11016; RRID: AB_2534083
  Alexa Fluor 594 Donkey Anti-Rat IgG (H+L)                                     Life Technologies          Cat\# A21209; RRID: AB_2535795
  Alexa Fluor 647 Donkey Anti-Rabbit IgG (H+L)                                  Life Technologies          Cat\# A-31573; RRID: AB_2536183
  Alexa Fluor 647 Donkey Anti-Goat IgG (H+L)                                    Life Technologies          Cat\# A-21447; RRID: AB_2535864
  Alexa Fluor 647 Donkey Anti-Rat IgG (H+L)                                     Jackson ImmunoResearch     Cat\# 712-605-153; RRID: AB_2340694
  Bacterial and Virus Strains                                                                              
  pLV\[shRNA\]-EGFP-control                                                     This paper                 N/A
  pLV\[shRNA\]-EGFP-CDH5-shRNA\#1                                               This paper                 N/A
  Chemicals, Peptides, and Recombinant Proteins                                                            
  BIO                                                                           Sigma-Aldrich              Cat\# B1686
  Human Fibronectin                                                             Corning                    Cat\# 354008
  SC-79                                                                         Millipore                  Cat\# 123871; CAS 305834-79-1
  BODIPY FL C~16~                                                               Invitrogen                 Cat\# D3821
  Tamoxifen                                                                     Sigma-Aldrich              Cat\# T5648
  Critical Commercial Assays                                                                               
  Trizol                                                                        Thermo Fisher Scientific   Cat\# 15596026
  PowerUp SYBR Green Master Mix                                                 Applied Biosystems         Cat\# A25742
  iScript Advanced cDNA Synthesis Kit                                           Bio-Rad                    Cat\# 172-5038
  Pierce BCA Protein Assay Kit                                                  Thermo Fisher Scientific   Cat\# 23227
  EGM-2 EC Growth Medium-2 Bullet Kit                                           Lonza                      Cat\# CC-4176
  Endothelial Cell Growth Medium MV 2                                           PromoCell                  Cat\# C-22121
  SuperSignal West Femto Maximum Sensitivity Substrate Kit                      Thermo Fisher Scientific   Cat\# 34095
  Experimental Models: Cell Lines                                                                          
  Human neonatal dermal lymphatic endothelial cells (HLECs): HMVEC-dLyNeo-Der   Lonza                      Cat\# CC-2812
  Human dermal lymphatic endothelial cells (HDLEC), juvenile foreskin           PromoCell                  Cat\# C-12216
  Experimental Models: Organisms/Strains                                                                   
  Mouse: *Tg(Tek-Cre)1Ywa*                                                      [@R28]                     N/A
  Mouse: *Lyve1tm1.1(EGFP/Cre)Cys*                                              [@R33]                     N/A
  Mouse: *Cdh5*^*flox*^                                                         This paper                 N/A
  Mouse: *Tg(Prox1-cre/ERT2)\#aTmak*                                            [@R4]                      N/A
  Mouse: *Tg(Prox1-EGFP)221Gsat/Mmcd*                                           [@R10]                     N/A
  Mouse: *Ctnnb1*^*tm1Mmt*^                                                     [@R24]                     N/A
  Oligonucleotides                                                                                         
  Please see [Table S1](#SD1){ref-type="supplementary-material"}                N/A                        N/A
  Recombinant DNA                                                                                          
  pLV\[shRNA\]-EGFP-control                                                     This paper                 N/A
  pLV\[shRNA\]-EGFP-CDH5-shRNA\#1                                               This paper                 N/A
  Software and Algorithms                                                                                  
  Adobe Photoshop                                                               Adobe system               <https://www.adobe.com/products/photoshop.html>
  ImageJ                                                                        N/A                        <https://imagej.nih.gov/ij/>
  GraphPad Prism 7                                                              GraphPad Software Inc      <https://www.graphpad.com/scientific-software/prism/>
  Zen 2 Pro                                                                     ZEISS                      <https://www.zeiss.com/microscopy/us/microscope-cameras.html>

###### Highlights

-   VE-cadherin regulates mechanotransduction signaling in the lymphatic vasculature

-   Loss of VE-cadherin impairs lymphatic valve formation and maintenance

-   VE-cadherin stabilizes β-catenin to enable regulation of PROX1 and FOXC2

-   AKT signaling regulates FOXC2 and is impaired in the absence of VE-cadherin
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